Medical equipment and services company Steris (NYSE: STE) reported calendar Q3 2026 (fiscal Q2 2027) results topping the market’s revenue expectations, with sales up 8.8% year on year to $1.59 billion. Its non-GAAP profit of $2.94 per share was 9.8% above analysts’ consensus estimates.

Is now the time to buy STE? Find out in our full research report (it’s free for active Edge members).

StockStory’s take

STERIS delivered a quarter that met Wall Street’s expectations, driven by strong underlying demand in its Healthcare and Life Sciences segments, as well as a notable contribution from tariff refunds. Management attributed revenue growth to higher procedure volumes, continued share gains in consumables, and service outperformance, with CEO Dan Carestio highlighting the “strength of our portfolio and commercial teams” in navigating a complex operating environment. Additionally, margin expansion was supported by $20 million in tariff refunds, though underlying margins faced some offset from inflation and increased R&D investment.

Looking ahead, STERIS has raised its full-year adjusted earnings per share guidance, reflecting confidence in continued growth across Healthcare, Life Sciences, and Applied Sterilization Technologies (AST). Management believes that ongoing investments in innovation, new product introductions, and the recently announced Xodus Medical acquisition will further expand recurring revenue and direct commercial presence. CFO Karen Burton emphasized that the outlook incorporates a stable healthcare demand environment, with growth supported by procedural increases, onshoring trends in Life Sciences, and incremental savings from targeted restructuring initiatives.

Key insights from management’s remarks

STERIS management credited the quarter’s performance to volume growth in core segments, favorable pricing, and one-time tariff refunds, while also highlighting strategic moves to strengthen its product portfolio and operational footprint.

• Healthcare segment momentum: Growth was led by the Gastrointestinal (GI) business, with consumables and service revenues both increasing 10%, driven by greater procedure volumes, share gains, and a recent acquisition in GI products.
• Service outperformance: The company’s Service business continued its strong trajectory, benefitting from higher customer adoption and procedural growth, which management noted as a key recurring revenue source.
• Life Sciences strength: The segment saw constant currency revenue up 18%, with capital equipment shipments boosted by a large single order exceeding $10 million. Management attributed growth to both pent-up demand and the broader trend of reshoring manufacturing operations.
• Tariff refunds impact margins: Approximately $20 million in tariff refunds added 130 basis points to adjusted gross margin, though management made clear these were non-recurring and not allocated to business segments, with future margin expansion expected to rely more on operational improvements.
• Xodus Medical acquisition: STERIS announced an agreement to acquire Xodus Medical, expanding its presence in surgical consumables and providing a direct operating room (OR) call point. Management expects this to bolster recurring revenue, citing a “high margin, high growth” product portfolio and complementary fit with existing offerings.

Drivers of future performance

STERIS’s outlook is shaped by stable procedure growth, continued innovation, and benefits from recent acquisitions and restructuring initiatives.

• Stable healthcare demand: Management expects procedural growth to remain at the lower end of historical ranges, especially in North America, but highlighted ongoing demand for sterilization and consumables as a consistent revenue foundation across hospital and outpatient settings.
• Reshoring and innovation in Life Sciences: The Life Sciences segment is positioned for high-single-digit growth, supported by increased capital equipment orders linked to onshoring and localization trends, as well as anticipated normalization after a period of pent-up demand.
• Operational efficiency and restructuring: Targeted facility realignment, product rationalization, and organizational changes are projected to generate $9 million in annualized savings, with partial realization in the upcoming year. Management believes these initiatives, combined with the integration of Xodus Medical, will further strengthen profitability and the recurring revenue base.

Catalysts in upcoming quarters

For the coming quarters, our analyst team will be monitoring (1) the integration and early performance of Xodus Medical within STERIS’s core healthcare business, (2) the realization of cost savings from ongoing restructuring and facility realignment, and (3) sustained order strength in Life Sciences as onshoring and capital equipment demand evolve. We will also track whether procedure volumes and service adoption remain consistent, underpinning overall growth.

STERIS currently trades at $257.12, up from $247.91 just before the earnings. At this price, is it a buy or sell? The answer lies in our full research report (it’s free).

High quality stocks for all market conditions

WHILE YOU’RE HERE: Top 9 Market-Beating Stocks. The best stocks don’t just beat the market once. They do it again. And again. Robust revenue growth, rising free cash flow, returns on capital that leave their competition in the dust. The market has already rewarded these businesses.

But our AI platform says the party isn’t over. Find out which 9 stocks made the cut this week — FREE. Get Our Top 9 Market-Beating Stocks for Free HERE.

Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.